Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Releases 87th Batch of Reference Drugs for Generic Quality Consistency

Fineline Cube Dec 30, 2024

The National Medical Products Administration (NMPA) has released the 87th batch of reference drugs for...

Company Drug

Bristol-Myers Squibb’s Opdivo Qvantig Receives FDA Approval for Expanded Indications

Fineline Cube Dec 30, 2024

Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that the US Food and...

Company Drug

HitGen Inc. Initiates Phase II Clinical Trial for HG146 in Adenoid Cystic Carcinoma

Fineline Cube Dec 30, 2024

China-based HitGen Inc. (SHA: 688222) has announced the commencement of the first patient enrollment in...

Company Deals

Reforgene Medicine Secures Hundreds of Millions in Financing for Gene Therapy Expansion

Fineline Cube Dec 30, 2024

Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds...

Company Deals

Xtalpi Inc. Partners with NCCS and Duke-NUS to Advance AI-Driven Drug Discovery

Fineline Cube Dec 30, 2024

Shenzhen-based QuantumPharm Inc., trading under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...

Company

Danaher Corporation Opens Joint Office in Beijing’s Chaoyang District

Fineline Cube Dec 30, 2024

US-based Danaher Corporation (NYSE: DHR), a leading science and tech services provider, has officially launched...

Company Deals

WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development

Fineline Cube Dec 30, 2024

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Policy / Regulatory

Hainan Free Trade Port Gets Green Light for Temporary Import of Special Medical Foods

Fineline Cube Dec 30, 2024

The State Administration for Market Regulation (SAMR) in China has given its approval in principle...

Company

GenFleet Therapeutics Submits IPO Application to HKEX, Backed by CITIC Securities

Fineline Cube Dec 29, 2024

On December 27, 2024, GenFleet Therapeutics, a biopharmaceutical company based in Shanghai, submitted its application...

Company

Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO

Fineline Cube Dec 29, 2024

On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024,...

Company

Dynamiker Biotechnology Receives Approval for IPO on Beijing Stock Exchange

Fineline Cube Dec 28, 2024

On December 27, 2024, the official website of the Beijing Stock Exchange announced that Dynamiker...

Company

MicroPort Endovascular MedTech’s Castor® Branched Stent Wins China Patent Gold Award

Fineline Cube Dec 28, 2024

The National Intellectual Property Administration has announced the winners of the 25th China Patent Awards,...

Company Drug

Daiichi Sankyo and AstraZeneca Withdraw EU Application for Datopotamab Deruxtecan in Lung Cancer

Fineline Cube Dec 27, 2024

Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced the voluntary...

Company

AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions

Fineline Cube Dec 27, 2024

UK major AstraZeneca’s (AZ, NASDAQ: AZN) China unit has announced a new round of structural...

Company Drug Hospital Medical Device Policy / Regulatory

Beijing Releases List of Novel Drugs and Technologies Exempt from CHS-DRG Payment Scheme

Fineline Cube Dec 27, 2024

The Beijing Municipal Medical Insurance Bureau has released the list of the first batch of...

Company Deals Drug

Johnson & Johnson Secures Licensing Deal with Kaken Pharmaceutical for STAT6 Program

Fineline Cube Dec 27, 2024

US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...

Company Deals

Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach

Fineline Cube Dec 27, 2024

China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...

Company Drug

Auzone Submits NDA for Oral Edaravone TTYP01 to Treat ALS

Fineline Cube Dec 27, 2024

Auzone Biological Technology has announced the submission of a New Drug Application (NDA) for its...

Company Drug

Pediatrix Therapeutics’ Neffy NDA Accepted by NMPA for Allergy Treatment

Fineline Cube Dec 27, 2024

China-based Pediatrix Therapeutics has announced that the New Drug Application (NDA) for its neffy (epinephrine...

Company Deals

Immunochina Pharmaceuticals and Cell Store Partner to Advance Cell Therapy Commercialization in China

Fineline Cube Dec 27, 2024

Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering...

Posts pagination

1 … 228 229 230 … 656

Recent updates

  • NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
  • Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
  • AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.